相关实验视频

Updated: Sep 20, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

在老年患者中治疗新诊断的扩散性大B细胞淋巴瘤R-mini-CHOP:单中心分析后期观察性研究

N L Lai1, P C Bee2

  • 1Hospital Kuala Lumpur, Department of Medicine, Kuala Lumpur, Malaysia. jere_lai91@hotmail.com.

The Medical journal of Malaysia
|May 29, 2025
PubMed

Insights

在马来西亚的老年患者中,R-mini-CHOP化疗的整体应答率为50%,这些患者患有扩散型大B细胞淋巴瘤 (DLBCL). 这表明R-mini-CHOP可能不足以治疗晚期DLBCL,因此需要更好的工具来指导治疗选择.

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 老年医学 老年医学

背景情况:

  • 扩散型大B细胞淋巴瘤 (DLBCL) 是老年人常见的一种非霍奇金淋巴瘤 (NHL).
  • 标准的R-CHOP化疗在老年人中可能具有挑战性,原因是并发症和副作用.
  • 建议降低剂量的R-mini-CHOP用于老年人和脆弱的DLBCL患者.

研究的目的:

  • 评估R-mini-CHOP在马来西亚新诊断的老年DLBCL患者的有效性和安全性.
  • 评估治疗反应,生存结果和与R-mini-CHOP治疗相关的并发症.

主要方法:

  • 在65岁以上的DLBCL患者接受R-mini-CHOP治疗后期分析.
  • 总体响应率 (ORR) 在六个周期后评估;不包括转变或复发/耐药淋巴瘤.
  • 二级分析包括人口因素,并发症和生存率 (无进展和整体).

主要成果:

  • 研究了33名老年DLBCL患者 (平均年龄为78岁);63.6%的人患有晚期 (III/IV) 疾病.
  • 总体响应率 (ORR) 为50.0% (16/32名患者),其中43.7%的患者实现了完全响应.
  • 达到ORR与早期疾病相关,并显著改善了无进展和整体存活率.

结论:

  • 与R-mini-CHOP观察到的ORR低于其他队列的ORR,这表明对高级DLBCL的潜在不足.
  • 建议使用老年预后工具来识别可能从全剂量R-CHOP中受益的老年患者.
  • 优化治疗选择对于改善老年DLBCL患者的反应和生存至关重要.
抽象的

No abstract available in PubMed .

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Enhancing Tumor Content through Tumor Macrodissection10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.7K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K